LIVE UPDATES: Fed Chair Jerome Powell to deliver major speech at Jackson Hole
In a recent transaction, Alfred Sandrock, President and CEO of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech company with a market capitalization of $240 million and strong financial health indicators, sold 16,644 shares of common stock. The shares were sold at a weighted average price of $4.45, totaling approximately $74,065. This transaction was part of a sell-to-cover election to satisfy tax withholding obligations related to the vesting of restricted stock units. Following this sale, Sandrock holds 308,518 shares directly. The shares were sold in multiple transactions with prices ranging from $4.13 to $5.00. According to InvestingPro, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 8.45, suggesting robust liquidity. The stock appears undervalued based on InvestingPro’s Fair Value analysis, with 12+ additional ProTips available for subscribers.
In other recent news, Voyager Therapeutics has announced a shift in its gene therapy program for amyotrophic lateral sclerosis (ALS). The company’s development candidate VY9323 did not meet the desired standards, leading to a delay in the investigational new drug (IND) application previously slated for mid-2025. Despite this, Voyager Therapeutics’ cash runway is expected to extend into mid-2027, and its other gene therapy programs remain unaffected. The company anticipates IND filings in 2025 for gene therapy candidates targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ataxia, in collaboration with Neurocrine (NASDAQ:NBIX) Biosciences.
Furthermore, H.C. Wainwright has maintained its Buy rating and a price target of $30.00 for Voyager Therapeutics. The firm expressed optimism about Voyager Therapeutics’ upcoming studies and anticipated data releases concerning its tau-targeting therapies, VY7523 and VY1706. Similarly, Citi has initiated a Buy rating for Voyager Therapeutics, with a price target set at $12.00, highlighting the company’s strong gene therapy pipeline. These are among the recent developments involving Voyager Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.